2012 ACR/ARHP Annual Meeting

November 9-14, 2012. Washington, DC.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1558

“It Gets Me Down Every Single Day”: Are Men with Rheumatoid Arthritis Getting the Support They Need?
Abstract Number: 2338

1,25(OH)₂D₃ Modulates the Migration Pattern of Th17 Cells From Patients with Rheumatoid Arthritis
Abstract Number: 1838

10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study
Abstract Number: 490

12- and 24-Week Patient-Reported Outcomes From a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 568

14-3-3 Eta Is a Modifiable Serum Biomarker That Marks Adalimumab Response in Psoriatic Arthritis
Abstract Number: 977

14-3-3 Eta Is a Novel Citrullination Target in Rheumatoid Arthritis That Enhances Diagnostic Utility in Anti-CCP Negative Patients
Abstract Number: 2178

18-Fludeoxyglucose Positron Emission Tomography Is a Valuable Marker of Activity of Interstitial Lung Disease in Primary Sjogren’s Syndrome
Abstract Number: 383

2002-04 Vs.2007-09: Initiation of Combination, and Tapering/Discontinuation (DC) Patterns of TNFi and MTX in a US (RA) Patient Registry: Analysis with CDAI Scores
Abstract Number: 769

2010 ACR/EULAR Rheumatoid Arthritis Classification Criteria Predicts Radiogical, but Not Clinical Outcomes At 18 Months Into Disease in a Canadian Early Arthritis Cohort
Abstract Number: 2487

24-Week Results of a Blinded Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/ Januse Kinase 2 Inhibitor, in Combination with Traditional Disease Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Abstract Number: 58

5 Million Patients and Not 0.34% Is Worrisome: Burden of Rheumatoid Arthritis in India Based On a Bone and Joint Decade India Community Oriented Program for Control of Rheumatic Disease
Abstract Number: 2218

5 Year Safety, Efficacy, and Radiographic Data in Patients with Active Psoriatic Arthritis Treated with Golimumab: Results From the Long-Term Extension of a Randomized, Placebo-Controlled Study
Abstract Number: 1547

A 4 Plus 2 Infusion Protocol of Rituximab Provides Long-Term Beneficial Effects in Patients with HCV-Associated Mixed Cryoglobulinemia with Membranoproliferative Nephritis and Severe Polyneuropathy
Abstract Number: 296

A Brazilian Multicenter Study of 71 Children and Adolescents with Takayasu’s Arteritis
Abstract Number: 1880

A Brazilian Portuguese Validation of the Revised Fibromyalgia Impact Questionnaire (FIQR)

1
2
3
…
180
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].